

19 November 2025

2025 Annual General Meeting Chair's Address

Dear Shareholders,

As Chair of the Board of Directors, it is my pleasure to address you today and to report on a year of strong progress for Bio-Gene as we continue advancing the development and commercial readiness of our two proprietary insecticidal active ingredients, Flavocide® and Qcide®. Both are designed to address a clear and growing global need for new, biologically derived insect control solutions. With resistance to existing insecticides increasing, and regulatory pressure on traditional insecticides rising around the world, the market need for our new pest control solutions has never been greater.

Throughout the past year, we made good progress across our development programs. For Flavocide, a series of regulatory-enabling safety studies are underway and being advanced and are being conducted on the basis of feedback that we received from the Australian regulator. These studies are all required for our future applications for regulatory approval and will also assist us in building a robust, globally relevant data package. In parallel, we completed pilot-scale manufacturing of Flavocide with Rallis India, confirming scalability and product consistency – an essential requirement for future commercial supply.

New efficacy data generated during the year further reinforced the potential of Flavocide. Researchers at Purdue University in the United States presented compelling laboratory results showing that Flavocide achieved more than 90 per cent mortality against *Ixodes scapularis* nymphs—the primary vector of Lyme disease—with residual activity lasting up to four weeks under controlled conditions. These results, produced within a vector control program being funded by the US Centers for Disease Control, highlight Flavocide's potential across both public health and animal health applications and demonstrate the versatility of our active ingredients when formulated for different use cases.

For Qcide, our work in Far North Queensland has continued to deliver improvements in both yield and production efficiency. Through expansion for seed production, plantation optimisation and new biomass pre-conditioning techniques developed in collaboration with James Cook University, we are strengthening the long-term viability of Qcide supply and reducing cost of Qcide production.

Our commercial engagement has continued to broaden, with a range of programs ongoing at Envu, Clarke Mosquito Control, Evergreen Garden Care and STK Bio-Ag aimed at advancing applications across public health, home garden, crop protection and consumer markets. These partnerships provide strong third-party validation of our actives and ensure our technology is being shaped and refined with input from experienced global industry participants.

Bio-Gene Technology Limited

ABN: 32 071 735 950

Level 6, 400 Collins Street, Melbourne, VIC 3000

19 November 2025

Qcide also recently achieved an important milestone with its approval for listing by the Organic Materials Review Institute (**OMRI**) in the United States under the USDA National Organic Program. This confirms that Qcide is suitable for use in certified organic production systems and allows us to use the OMRI Listed seal in our technical and marketing materials. While it is not a regulatory approval, this listing significantly strengthens Qcide's position in the growing organic and sustainable agriculture markets and supports future pathways for additional Qcide-based formulations.

Our broader research and development program continues to benefit from strong external validation. Earlier in the financial year, Bio-Gene was awarded two competitive grants from the U.S. Department of Defense's Deployed Warfighter Protection program, supporting work on both a wearable mosquito repellent incorporating Flavocide and a sprayable Qcide formulation for public health pests. These grants are a clear signal of the international interest in novel insect control solutions with new modes of action and favourable safety profiles.

Recently we've also completed a review of our pipeline and strategic priorities, with eight product opportunities remaining active. This review has opened new potential commercial opportunities, and we look forward to bringing further updates on these as they come to fruition.

Our management team has extended on this with recent business development meetings in several key international jurisdictions as well as attendance at key pest control conferences and symposiums.

Looking ahead, Bio-Gene enters its next phase of growth with strong momentum. Our priorities include progressing the next suite of regulatory-enabling studies for Flavocide, continuing formulation development with our partners, expanding the certification and regulatory pathways for Qcide, and further building the commercial data packages needed to support market entry in key global segments. Rising global demand for safer, biologically derived pest control products continues to align strongly with Bio-Gene's technology, and we are encouraged by the breadth of opportunities emerging across public health, agriculture and consumer markets.

On behalf of the Board, I thank our shareholders for their support at this key development phase. I would also like to acknowledge our partners, collaborators and the Bio-Gene team for their dedication throughout the year. Their collective efforts place us in a strong position as we work to realise the commercial potential of our technology.

For further information, please contact:

Bio-Gene Technology Limited:
E: bgt.info@bio-gene.com.au

Matthew Wright
NWR Communications
E: matt@nwrcommunications.com.au
M: 0451 896 420

19 November 2025

About Bio-Gene Technology Limited

Bio-Gene is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance and toxicity. Its unique products are based on a naturally occurring class of compounds proven to overcome resistance to control pests with minimal impact on human health and the environment.

Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. They provide new options derived from nature to meet market demand for effective and safe pest management solutions.

Flavocide® and **Qcide®** are registered trademarks of Bio-Gene Technology Limited in Australia.

For personal use only